Compositions and methods of treating cancer using lipid agonists and receptors thereof

Abstract

Provided herein are methods for preventing or treating cancer in a subject comprising overexpressing at least one Receptor for a lipid agonist, such as G-protein receptors for Resolvin. Such methods may be combined with administering Resolvins, or lipoxins and their analogs, of said Receptors to enhance the pro-resolution effects of the Resolvins, or lipoxins and their analogs, in the local, inflammatory environment where cancer cells are already present.

What is claimed: 
     
       1. A method for treating lung cancer in a subject, wherein the subject comprises cells that overexpress Receptor for Resolvin E1 (ERV1), the method comprising:
 administering at least one Resolvin E series lipid agonist to the subject, wherein the at least one Resolvin E series lipid agonist is selected from the group consisting of di-hydroxy members of the Resolvin E series and tri-hydroxy members of the Resolvin E series. 
 
     
     
       2. The method of  claim 1 , wherein the at least one Resolvin E series lipid agonist is selected from the group consisting of Resolvin E1, Resolvin E2, and Resolvin E3. 
     
     
       3. The method of  claim 1 , wherein the at least one Resolvin E series lipid agonist comprises Resolvin E 1. 
     
     
       4. The method of  claim 1 , wherein the at least one Resolvin E series lipid agonist is administered systemically, wherein the systemic administration is selected from the group consisting of oral, intravenous, intradermal, intraperitoneal, subcutaneous, and intramuscular administration. 
     
     
       5. The method of  claim 1 , wherein the at least one Resolvin E series lipid agonist is administered intratumorally or peritumorally. 
     
     
       6. The method of  claim 1 , wherein the subject is treated with at least one additional anti-cancer agent, wherein the anti-cancer agent is selected from the group consisting of paclitaxel, cisplatin, topotecan, gemcitabine, bleomycin, etoposide, carboplatin, docetaxel, doxorubicin, topotecan, cyclophosphamide, trabectedin, olaparib, tamoxifen, letrozole, and bevacizumab. 
     
     
       7. The method of  claim 1 , wherein the subject is concurrently treated with cisplatin. 
     
     
       8. The method of  claim 1 , wherein the subject is treated with at least one additional anti-cancer therapy, wherein the anti-cancer therapy is radiation therapy, chemotherapy, or surgery. 
     
     
       9. The method of  claim 1 , wherein the subject is a mammal. 
     
     
       10. The method of  claim 1 , wherein the subject is a human. 
     
     
       11. The method of  claim 1 , wherein an inflammatory response is inhibited or reduced in the subject, wherein the inhibition or reduction in the inflammatory response results in a decreased expression of the NF-κB, IL-6, and IL-8 genes. 
     
     
       12. The method of  claim 1 , wherein an angiogenic response is inhibited or reduced in the subject, wherein the inhibition or reduction in the angiogenic response results in a decreased expression of the Ang1, Ang2, and VEGF genes. 
     
     
       13. The method of  claim 1 , wherein malignancy is inhibited or reduced in the subject. 
     
     
       14. The method of  claim 1 , wherein tumor necrosis is enhanced or increased in the subject.